HTFL Heartflow, Inc.
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.…
Industry Peers
Health Information ServicesKey Statistics
About Heartflow (NASDAQ: HTFL)
›
Heartflow (NASDAQ: HTFL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 843 employees.
The shares were at 44.63 USD on 19 November 2026, up 63.4% over 52 weeks. Its 52-week range is 20.13 USD to 60.65 USD: the price is 26.4% below the high and 121.7% above the low.
At a market capitalisation of 3.92B USD, it trades at 66.6 times trailing earnings. The median trailing P/E of its 14 largest Health Information Services peers is 40.2, a premium of 66% for HTFL.
Heartflow reports return on equity of -38.8%, an operating margin of -30.0% and revenue up 57.4% year over year.
It holds more cash than debt, a net cash position of 141.80M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 65.00 USD is 45.6% above the current price. The next earnings report is expected on 17 March 2027.